| Primary |
| Product Used For Unknown Indication |
34.5% |
| Drug Use For Unknown Indication |
31.5% |
| Myelodysplastic Syndrome |
12.7% |
| Acute Myeloid Leukaemia |
5.2% |
| Prophylaxis |
3.1% |
| Hypertension |
2.0% |
| Pain |
1.4% |
| Mds |
1.3% |
| Constipation |
1.2% |
| Nausea |
1.2% |
| Infection Prophylaxis |
1.1% |
| Chronic Myelomonocytic Leukaemia |
0.8% |
| Acute Myeloid Leukemia |
0.7% |
| Diabetes Mellitus |
0.6% |
| Neutropenia |
0.6% |
| Pneumonia |
0.5% |
| Thrombosis Prophylaxis |
0.4% |
| Refractory Anaemia With An Excess Of Blasts |
0.4% |
| Infection |
0.4% |
| Antiemetic Supportive Care |
0.4% |
|
| Death |
16.8% |
| Sepsis |
11.3% |
| Pneumonia |
10.4% |
| Thrombocytopenia |
7.5% |
| Acute Myeloid Leukaemia |
6.4% |
| White Blood Cell Count Decreased |
5.2% |
| Pyrexia |
4.8% |
| Febrile Neutropenia |
4.2% |
| Disease Progression |
3.5% |
| Myelodysplastic Syndrome |
3.5% |
| Septic Shock |
3.4% |
| Pancytopenia |
3.1% |
| Vomiting |
3.1% |
| Neutropenia |
2.9% |
| No Therapeutic Response |
2.8% |
| Myelodysplastic Syndrome Transformation |
2.6% |
| Infection |
2.5% |
| Platelet Count Decreased |
2.1% |
| Cerebral Haemorrhage |
1.9% |
| Neutrophil Count Decreased |
1.8% |
|
| Secondary |
| Product Used For Unknown Indication |
53.8% |
| Drug Use For Unknown Indication |
26.9% |
| Myelodysplastic Syndrome |
7.9% |
| Acute Myeloid Leukaemia |
2.4% |
| Prophylaxis |
1.3% |
| Hypertension |
1.0% |
| Mds |
1.0% |
| Constipation |
0.9% |
| Pain |
0.7% |
| Infection Prophylaxis |
0.6% |
| Nausea |
0.6% |
| Acute Myeloid Leukemia |
0.4% |
| Pneumonia |
0.4% |
| Neutropenia |
0.4% |
| Bronchitis |
0.4% |
| Iron Overload |
0.3% |
| Refractory Anaemia With An Excess Of Blasts |
0.3% |
| Premedication |
0.3% |
| Chronic Myelomonocytic Leukaemia |
0.2% |
| Infection |
0.2% |
|
| Pneumonia |
13.5% |
| White Blood Cell Count Decreased |
13.3% |
| Sepsis |
12.1% |
| Thrombocytopenia |
7.4% |
| Febrile Neutropenia |
5.9% |
| Pyrexia |
5.3% |
| Acute Myeloid Leukaemia |
4.7% |
| Neutrophil Count Decreased |
4.5% |
| White Blood Cell Count Increased |
4.0% |
| Platelet Count Decreased |
3.9% |
| Pancytopenia |
3.7% |
| No Therapeutic Response |
3.2% |
| Tumour Lysis Syndrome |
2.8% |
| Neutropenia |
2.6% |
| Death |
2.5% |
| Vomiting |
2.4% |
| Infection |
2.3% |
| Myelodysplastic Syndrome |
2.0% |
| Respiratory Failure |
2.0% |
| Septic Shock |
1.9% |
|
| Concomitant |
| Myelodysplastic Syndrome |
36.4% |
| Product Used For Unknown Indication |
12.3% |
| Iron Overload |
8.2% |
| Prophylaxis |
7.2% |
| Idiopathic Thrombocytopenic Purpura |
4.4% |
| Drug Use For Unknown Indication |
3.9% |
| Hypertension |
3.0% |
| Chemotherapy |
2.6% |
| Cord Blood Transplant Therapy |
2.5% |
| Acute Myeloid Leukaemia |
2.0% |
| Bone Marrow Conditioning Regimen |
2.0% |
| Paroxysmal Nocturnal Haemoglobinuria |
2.0% |
| Anaemia |
1.9% |
| Insomnia |
1.9% |
| Chronic Lymphocytic Leukaemia |
1.7% |
| Multiple Myeloma |
1.7% |
| Serum Ferritin Increased |
1.7% |
| Coronary Artery Disease |
1.6% |
| Cytomegalovirus Infection |
1.6% |
| Haemochromatosis |
1.6% |
|
| Myelodysplastic Syndrome |
9.2% |
| White Blood Cell Count Decreased |
9.2% |
| Weight Decreased |
8.5% |
| Thrombocytopenia |
7.2% |
| Death |
5.9% |
| Urinary Tract Infection |
5.9% |
| Acute Myeloid Leukaemia |
5.2% |
| Diarrhoea |
5.2% |
| Sepsis |
5.2% |
| Nausea |
3.9% |
| Platelet Count Decreased |
3.9% |
| Pyrexia |
3.9% |
| Red Blood Cell Count Decreased |
3.9% |
| Visual Field Defect |
3.9% |
| Vomiting |
3.9% |
| Anaemia |
3.3% |
| Myelofibrosis |
3.3% |
| Thrombotic Microangiopathy |
3.3% |
| Optic Ischaemic Neuropathy |
2.6% |
| Pancytopenia |
2.6% |
|
